Publications in collaboration with researchers from Cleveland Clinic (41)

2024

  1. A plain language summary of publication of the efficacy and safety of individualized niraparib dosing based on baseline body weight and platelet count in the PRIMA/ENGOT-OV26/GOG-3012 trial

    Future oncology (London, England), Vol. 20, Núm. 13, pp. 799-809

  2. Recurrence and tumor-related death after resection of hepatocellular carcinoma in patients with metabolic syndrome

    JHEP Reports, Vol. 6, Núm. 7

2023

  1. Alternative forms of portal vein revascularization in liver transplant recipients with complex portal vein thrombosis

    Journal of Hepatology, Vol. 78, Núm. 4, pp. 794-804

  2. Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab-bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study

    The Lancet. Oncology, Vol. 24, Núm. 12, pp. 1411-1422

  3. Minimally Invasive Versus Open Liver Resections for Hepatocellular Carcinoma in Patients With Metabolic Syndrome

    Annals of surgery, Vol. 278, Núm. 5, pp. e1041-e1047

  4. Model to predict major complications following liver resection for HCC in patients with metabolic syndrome

    Hepatology, Vol. 77, Núm. 5, pp. 1527-1539

  5. Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial

    Nature Medicine, Vol. 29, Núm. 6, pp. 1370-1378

  6. Prognostic value of isolated tumor cells in sentinel lymph nodes in low risk endometrial cancer: Results from an international multi-institutional study

    International Journal of Gynecological Cancer

  7. Prospective evaluation of the tolerability and efficacy of niraparib dosing based on baseline body weight and platelet count: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial

    Cancer, Vol. 129, Núm. 12, pp. 1846-1855

2022

  1. Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma Subtypes

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, Núm. 1, pp. 24-33

  2. Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, Núm. 7, pp. 483-494

  3. Genomic profiling for clinical decision making in lymphoid neoplasms

    Blood

  4. Minimally Invasive Donor Hepatectomy for Adult Living Donor Liver Transplantation An International, Multi-institutional Evaluation of Safety, Efficacy and Early Outcomes

    Annals of Surgery, Vol. 275, Núm. 1, pp. 166-174

  5. The International Association for the Study of Lung Cancer Thymic Epithelial Tumor Staging Project: Unresolved Issues to be Addressed for the Next Ninth Edition of the TNM Classification of Malignant Tumors

    Journal of Thoracic Oncology, Vol. 17, Núm. 6, pp. 838-851

  6. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

    Blood, Vol. 140, Núm. 11, pp. 1229-1253

2021

  1. ADAMTSL5 is an epigenetically activated gene underlying tumorigenesis and drug resistance in hepatocellular carcinoma

    Journal of Hepatology, Vol. 74, Núm. 4, pp. 893-906

  2. Comparison of Multimodal Therapies and Outcomes among Patients with High-Risk Prostate Cancer with Adverse Clinicopathologic Features

    JAMA Network Open, Vol. 4, Núm. 7

  3. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

  4. Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma

    Future Oncology, Vol. 17, Núm. 11, pp. 1295-1310

  5. Oncologic outcomes of endometrial cancer in patients with low-volume metastasis in the sentinel lymph nodes: An international multi-institutional study

    Gynecologic Oncology, Vol. 162, Núm. 3, pp. 590-598